NCT03013491 2025-06-17PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasCytomX TherapeuticsPhase 1/2 Terminated196 enrolled 28 charts
NCT01616199 2018-05-16Study of PX-866 and Vemurafenib in Patients With Advanced MelanomaSeagen Inc.Phase 1/2 Terminated24 enrolled